Legend Biotech Launches $10M ELITE Grant Program to Boost Multiple…

Event summary

Legend Biotech launched its inaugural ELITE Grant Program on October 1, 2026, with applications open through November 20, 2026.
The program will award grants in two categories: Emerging Educator and Emerging Innovator, focusing on multiple myeloma CAR-T research.
An independent steering committee of seven nationally recognized experts will oversee the grant selection process.
Recipients will be notified in December 2026 and invited to a recognition event in 2027.

The big picture

Legend Biotech's ELITE Grant Program is a strategic move to foster innovation in multiple myeloma treatment, aligning with the broader industry trend of investing in next-generation cell therapies. With over 3,000 employees and a strong partnership with Johnson & Johnson for CARVYKTI, Legend Biotech is positioning itself as a leader in the CAR-T therapy space. The program aims to support both education and innovation, potentially shaping the future of multiple myeloma care.

What we're watching

Research Impact: How the ELITE Program will accelerate next-generation CAR-T innovations in multiple myeloma.
Industry Leadership: Whether Legend Biotech can solidify its position as a pioneer in cell therapy through this initiative.
Talent Development: The pace at which early-career healthcare professionals will advance their careers through this program.